Trial Profile

Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tc 99m tilmanocept (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions
Sponsors Navidea Biopharmaceuticals

Most Recent Events

16 Jun 2018 Results assessing Tc 99M Tilmanocept Localization in Active Rheumatoid Arthritis (Ra) Subjects by Planar and Spect/Ct, presented at the 19th Annual Congress of the European League Against Rheumatism
14 Dec 2016 Status changed from recruiting to completed.
03 Nov 2016 According to a Navidea Biopharmaceuticals media release, to date, 17 of 18 patients have been dosed and imaged in the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com